期刊文献+

某三甲儿童医院甲氨蝶呤血药浓度监测及影响因素分析 被引量:1

Monitoring and Influencing Factors of Methotrexate Blood Concentration in a Grade Ⅲ Level A Hospital
下载PDF
导出
摘要 目的:监测我院使用大剂量甲氨蝶呤治疗急性淋巴细胞白血病及淋巴瘤患儿的血药浓度,并对影响因素进行分析。方法:采用回顾性研究方法,收集我院2015年6月至2017年9月使用大剂量甲氨蝶呤治疗的急性淋巴细胞白血病及淋巴瘤患儿的血药浓度监测报告共121份,归纳整理分析结果,探讨其影响因素。结果:121例甲氨蝶呤血药浓度监测报告中,24 h血药浓度有16例(13. 22%)超过危急值,最高值达72. 36μmol/L; 48 h、72 h血药浓度均能够维持在安全范围内,无超过危急值情况。尿液碱化对甲氨蝶呤的24 h血药浓度影响显著(P<0. 01)。结论:我院应进一步规范甲氨蝶呤使用方法,注意碱化尿液,加强血药浓度监测,以确保患儿用药安全。 Objective:To monitor the blood concentration of children with acute lymphoblastic leukemia and lymphoma treated with high-dose methotrexate in our hospital,and to analyze the influencing factors.Methods:Retrospective statistical analysis method was adopted.A total of 121 blood concentration monitoring reports were collected from children with acute lymphocytic leukemia and lymphoma treated with high-dose methotrexate in our hospital from June 2015 to Sept.2017,the results of the analysis were summarized and the influencing factors were discussed.Results:Of the 121 cases of methotrexate blood concentration monitoring reports,16 cases(13.22%)with the 24 h blood concentration exceeded the critical value,the highest value reached 72.36μmol/L.The blood concentration at 48 h and 72 h can be maintained within the safe range without exceeding the critical value.Urine alkalization had a significant effect on the 24 h blood concentration of methotrexate(P<0.01).Conclusion:Our hospital should further standardize the use of methotrexate,pay attention to the urine alkalization,and strengthen the blood concentration monitoring to ensure the safety of children.
作者 孙丽 任玲 安琪 刘红 Sun Li;Ren Ling;An Qi;Liu Hong(Xuzhou Children's Hospital of Xuzhou Medical University,Jiangsu Xuzhou 221000,China)
出处 《儿科药学杂志》 CAS 2019年第2期44-46,共3页 Journal of Pediatric Pharmacy
关键词 甲氨蝶呤 血药浓度监测 影响因素 methotrexate blood concentration monitoring influencing factors
  • 相关文献

参考文献5

二级参考文献17

  • 1杨丽华,卢新天,卢炜,吴克华,华瑛,赵卫红.大剂量甲氨喋呤在急性白血病患儿体内的群体药动学[J].中国药学杂志,2005,40(13):1007-1012. 被引量:25
  • 2Wolform C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour- high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia [ J ]. J Clin Oneol, 1993,11 ( 5 ) : 827-833.
  • 3Wang YM, Fujimoto T. Clinical pharmacyokinetics of methotrexate in children[J]. Clin Pharmacokinet, 1984, 9(4) :335-348.
  • 4Schrappe M, Reiter A, Ludwnig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy : Results of trial All - BFM90 [ J ]. Blood, 2000,95( 11 ) :3310 - 3322.
  • 5Reiter A,Schrappe M,Tiemann M,et al. Improved treament result in childhood B - Cell neoplasms with Tailored intensification of therapy: A report of the Berlin - Frankfurt - Munster Group trial NHL - BFM 90 [J]. Blood, 1999,94 (10) : 3294 - 3306.
  • 6Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia [ J ]. Lancet Oncol, 2008,9 (3) : 262 -264.
  • 7Esteve MA, Devictor- Pierre B, Galy G,et al. Severe acute toxicity associated with high - dose methotrexate (MTX) therapy:Use of therapeutic drug monitoring and test - dose to guide carboxypeptidase G2 rescue and MTX continuation [ J ]. Eur J Clin Pharmacol, 2007,63 ( 1 ) :39 - 42.
  • 8Muller J, Kralovanszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high - dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism [ J ]. Anticancer Res, 2008,28 (5B) :3051 - 3054.
  • 9Gerber DE, Grossman SA, Batchelor T, et al. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma [ J ]. Cancer Chemother Pharmacol, 2007,59(6) :817 -823.
  • 10窦云,徐为人,李泽辉.儿童急性淋巴细胞白血病治疗中甲氨蝶呤血药浓度与不良反应的相关性研究[J].药学服务与研究,2008,8(3):177-180. 被引量:5

共引文献813

同被引文献8

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部